Study Finds Increased Risk of MGUS in Vietnam Vets Exposed to Agent Orange
the ONA take:
Vietnam War veterans exposed to Agent Orange, an herbicidal agent used for warfare, have more than a 2-fold increased risk for monoclonal gammopathy of undetermined significance (MGUS), according to a new study published online ahead of print in JAMA Oncology.
MGUS is a precursor to multiple myeloma. Patients with MGUS have lower antibody levels, plasma cells in the bone marrow, and no symptoms. Therefore, no treatment is indicated for patients with MGUS, but patients should be followed up every 6 months to determine if MGUS has transformed into multiple myeloma or a similar lymphoproliferative disorder.
For the study, a team of researchers led by Ola Landgren, MD, PhD, of Memorial Sloan Kettering Cancer Center in New York analyzed samples from 958 male veterans of the Vietnam War. Half of those were Operation Ranch Hand veterans who participated in aerial Agent Orange spray missions.
"Our findings of increased MGUS risk among Ranch Hand veterans support an association between Agent Orange exposure and multiple myeloma," the study concludes.
Agent Orange was widely used during the Vietnam War.
Sign Up for Free e-newsletters
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- Aggressive Therapy Provides No Additional Advantage in Metastatic Prostate Cancer
- Excretion of Volatile Organic Compounds Higher in AYAs Using Vaping Products
- FDA, ASHP Actions to Prevent or Manage Chemotherapy Drug Shortages
- Risk for Cardiovascular Disease Higher in Survivors of Testicular Cancer
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Sexual Quality of Life Decreased During, After Chemotherapy for Digestive Cancers
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- Approach and Management of Checkpoint Inhibitor-related Immune Hepatitis
- Revised AJCC8 Demonstrates Superior Tumor Classification for HNCSCC
- Oral Androgen Receptor Inhibitor Granted FDA Approval for Nonmetastatic CRPC
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|